{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"FUZE","nct_id":"NCT03834220","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=fuze-nct03834220. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with biliary tract cancer were included in this cohort to receive Debio 1347 80 milligrams (mg) tablets, orally, once daily (QD), from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 20 weeks).","label":"Cohort 1: Debio 1347 (Biliary Tract Cancer)","type":"EXPERIMENTAL"},{"description":"Participants with urothelial cancer were included in this cohort to receive Debio 1347 80 mg tablets, orally, QD, from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 5.86 weeks).","label":"Cohort 2: Debio 1347 (Urothelial Cancer)","type":"EXPERIMENTAL"},{"description":"Participants with all other solid tumor histologies were included in this cohort to receive Debio 1347 80 mg tablets, orally, QD, from Day 1 to Day 28 in 28-day cycles until the occurrence of disease progression or unacceptable toxicity (up to a median duration of 8.14 weeks).","label":"Cohort 3: Debio 1347 (All Other Solid Tumor Histologies)","type":"EXPERIMENTAL"}],"collaborators":["Caris Life Sciences","Optimal Research (Just In Time sites)"],"completion_date":{"date":"2022-01-04","type":"ACTUAL"},"conditions":["Solid Tumor"],"enrollment":{"count":63,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Debio 1347","otherNames":[],"type":"DRUG"}],"last_update":"2024-02-07","lead_sponsor":"Debiopharm International SA","official_title":"A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2020-12-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) as Centrally Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Criteria","timeFrame":"Up to disease progression or end of study (up to 1 year and 9 months)"}],"references":[],"start_date":{"date":"2019-03-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)","url":"https://clinicaltrials.gov/study/NCT03834220"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/fuze-nct03834220"}